Oligonucleotide therapeutics and application thereof
AssigneeVacino Biotech Co., Ltd.
InventorsJia-Ming CHANG, Chiung-Wen Liou
Life of this patent
Estimating the term…
Abstract
The present invention relates to oligonucleotide therapeutics. The oligonucleotide therapeutics have at least an oligonucleotide conjugated to a dodecylamine at the 5′ end of the oligonucleotide. The oligonucleotide therapeutics may further contain a polyethylene glycol (PEG) conjugated to the dodecylamine at the amino terminus of the dodecylamine, and may further contain a peptide linker disposed between the dodecylamine and the PEG.
Claims20
An oligonucleotide therapeutic, comprising an oligonucleotide and a dodecylamine, wherein a first carbon of the dodecylamine is conjugated to the oligonucleotide at a 5′ end of the oligonucleotide, and an amino group of the dodecylamine is located at a twelfth carbon of the dodecylamine.
Dependencies are inferred from the claim text.